Amina Ahmed, MD, Paula Anastasia, RN, MN, AOCN, and Ali McBride, PharmD, MS, discuss the benefits and risks of using combination therapy with a PARP inhibitor and bevacizumab as first-line maintenance therapy in ovarian cancer.
Combination Therapy as Maintenance in Ovarian Cancer
Associate Chief Medical Officer
Division Gynecology, Dept OBGYN
Cancer Center of Rush University Medical Center
Chicago, IL
Division Gynecology, Dept OBGYN
Cancer Center of Rush University Medical Center
Chicago, IL
Clinical Coordinator
The University of Arizona Cancer Center
Tucson, AZ
The University of Arizona Cancer Center
Tucson, AZ
GYN Oncology Clinical Nurse Specialist
UCLA Health
Los Angeles, CA
UCLA Health
Los Angeles, CA
